Literature DB >> 12757237

Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand.

Viroj Verachai1, Tipwan Phutiprawan, Apiradee Theamboonlers, Teeraporn Chinchai, Srivilai Tanprasert, Bart L Haagmans, Albert D M E Osterhaus, Yong Poovorawan.   

Abstract

Hepatitis C virus (HCV) is an infectious agent that has the potential to cause chronic liver disease, cirrhosis and hepatocellular carcinoma. We determined the prevalence and genotypes of HCV infection among groups of drug addicts: intravenous drug users (n = 134), methamphetamine users (n = 100), inhaled-drugs users (n = 19) and alcoholics (n = 50); a group of blood donors acted as a control. The control group consisted of 179 randomly-selected anti-HCV positive samples: these were subjected to HCV RNA screening and genotyping. The anti-HCV test was performed by ELISA: HCV RNA screening was by nested RT-PCR that employed primers from the 5' noncoding region. The genotype assay was based upon analysis of the 5' NCR amplified sequences and RFLP. Hepatitis C virus was highly prevalent among all groups of drug addicts (12-70%). In 2000. among the new blood donors (n = 66,340) at the National Blood Center, Thai Red Cross, anti-HCV prevalence amounted to 0.98%. The HCV genotype distribution showed that the most prevalent genotype was 3a, followed by 1b and 6a. Our data demonstrated the very high prevalence of HCV infection in IVDUs, a finding that is consistent with the blood-borne nature of the virus. In order to curb HCV infection, a determined effort to educate both the general population and high-risk groups is required; such a program of education would address both general and particular methods of transmission, especially the use of non-sterile needles etc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12757237

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  11 in total

1.  Prevalence and risk factors for hepatitis C virus infection among young Thai men.

Authors:  Anchalee Jatapai; Kenrad E Nelson; Thippawan Chuenchitra; Khunakorn Kana; Sakol Eiumtrakul; Ekachai Sunantarod; Ram Rangsin
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

2.  A shift in the hepatitis C virus genotype dominance in blood donor samples from Thailand.

Authors:  Anchalee Sistayanarain; Duangkamol Kunthalert; Yaovaluk Vipsoongnern
Journal:  Mol Biol Rep       Date:  2010-11-27       Impact factor: 2.316

3.  HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.

Authors:  M Florencia Etcheverry; Paula J Lum; Jennifer L Evans; Emilia Sanchez; Elisa de Lazzari; Eva Mendez-Arancibia; Ernesto Sierra; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

4.  Genetic variation of hepatitis C virus in a cohort of injection heroin users in Wuhan, China.

Authors:  Jin-Song Peng; Xu Wang; Man-Qing Liu; Dun-Jin Zhou; Jie Gong; Han-Ming Xu; Jian-Ping Chen; Hong-Hao Zhu; Wang Zhou; Wen-Zhe Ho
Journal:  Virus Res       Date:  2008-03-18       Impact factor: 3.303

5.  Methamphetamine administration modifies leukocyte proliferation and cytokine production in murine tissues.

Authors:  Habibullah Peerzada; Jay A Gandhi; Allan J Guimaraes; Joshua D Nosanchuk; Luis R Martinez
Journal:  Immunobiology       Date:  2013-02-27       Impact factor: 3.144

6.  Genotypic distribution of hepatitis C virus in Thailand and Southeast Asia.

Authors:  Rujipat Wasitthankasem; Sompong Vongpunsawad; Nipaporn Siripon; Chutima Suya; Phrutsada Chulothok; Kasemporn Chaiear; Pairaya Rujirojindakul; Sawan Kanjana; Apiradee Theamboonlers; Pisit Tangkijvanich; Yong Poovorawan
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

7.  Prevalence and seroincidence of hepatitis B and hepatitis C infection in high risk people who inject drugs in china and Thailand.

Authors:  J Brooks Jackson; Liu Wei; Fu Liping; Apinun Aramrattana; David D Celentano; Louise Walshe; Yi Xing; Paul Richardson; Ma Jun; Geetha Beauchamp; Deborah Donnell; Yuhua Ruan; Liying Ma; David Metzger; Yiming Shao
Journal:  Hepat Res Treat       Date:  2014-03-27

8.  Estimating the Impact of Expanding Treatment Coverage and Allocation Strategies for Chronic Hepatitis C in a Direct Antiviral Agent Era.

Authors:  Kittiyod Poovorawan; Wirichada Pan-Ngum; Lisa J White; Ngamphol Soonthornworasiri; Polrat Wilairatana; Rujipat Wasitthankasem; Pisit Tangkijvanich; Yong Poovorawan
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

9.  Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.

Authors:  Rujipat Wasitthankasem; Nawarat Posuwan; Preeyaporn Vichaiwattana; Apiradee Theamboonlers; Sirapa Klinfueng; Viboonsak Vuthitanachot; Napha Thanetkongtong; Siriporn Saelao; Monthana Foonoi; Apinya Fakthongyoo; Jamorn Makaroon; Klaita Srisingh; Duangporn Asawarachun; Somchai Owatanapanich; Norra Wutthiratkowit; Kraisorn Tohtubtiang; Pornsak Yoocharoen; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

10.  Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.

Authors:  Rujipat Wasitthankasem; Preeyaporn Vichaiwattana; Nipaporn Siripon; Nawarat Posuwan; Chompoonut Auphimai; Sirapa Klinfueng; Napha Thaneskongtong; Viboonsak Vuthitanachot; Supapith Saiyatha; Chaiwat Thongmai; Sarawut Suwanpatoomlerd; Saowakon Sochoo; Natnada Pongsuwan; Kittiyod Poovorawan; Pisit Tangkijvanich; Sompong Vongpunsawad; Yong Poovorawan
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.